Establishment Labs Holdings Inc. $ESTA Shares Bought by Sofinnova Investments Inc.

Sofinnova Investments Inc. increased its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 163.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 28,366 shares of the company’s stock after buying an additional 17,579 shares during the quarter. Sofinnova Investments Inc.’s holdings in Establishment Labs were worth $2,067,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Quarry LP purchased a new stake in Establishment Labs during the 3rd quarter worth approximately $34,000. Kestra Advisory Services LLC purchased a new stake in Establishment Labs during the 4th quarter worth approximately $47,000. Osaic Holdings Inc. increased its stake in Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares in the last quarter. Truist Financial Corp purchased a new stake in Establishment Labs during the 4th quarter worth approximately $200,000. Finally, PharVision Advisers LLC purchased a new stake in Establishment Labs during the 3rd quarter worth approximately $203,000. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have commented on ESTA. Canaccord Genuity Group boosted their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Wall Street Zen lowered Establishment Labs from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Stephens boosted their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. TD Cowen reiterated a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. Finally, Mizuho boosted their price objective on Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $87.14.

Insiders Place Their Bets

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the transaction, the director directly owned 927,504 shares in the company, valued at approximately $69,952,351.68. This represents a 10.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 330,000 shares of company stock valued at $22,854,538 in the last ninety days. Corporate insiders own 9.99% of the company’s stock.

Establishment Labs Price Performance

ESTA stock opened at $84.21 on Tuesday. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. The business has a 50 day simple moving average of $69.33 and a 200-day simple moving average of $69.28. The firm has a market capitalization of $2.48 billion, a PE ratio of -56.52 and a beta of 1.11. Establishment Labs Holdings Inc. has a 1 year low of $33.35 and a 1 year high of $86.00.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The company had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. Establishment Labs’s revenue for the quarter was up 44.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.70) earnings per share. Equities research analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.